Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia
NCT04825561Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dutasteride in androgenetic alopecia (AGA), sponsored by Addpharma, Inc.. Started Jun 2021; status: completed.
02
Drugs
dutasteride
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04825561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825561.